Notícias

VEEV's strong Q1, growing Vault CRM migrations and AI expansion support growth, though life sciences CRM market saturation poses risks.

Despite GE HealthCare's underperformance relative to the S&P 500 Index over the past year, analysts are moderately optimistic about the stock’s prospects.

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Veeva Systems’ first quarter saw meaningful progress across its core business lines, with management attributing the results to broad-based customer demand and product execution in both R&D and commercial segments. CEO Peter Gassner highlighted the launch of Veeva’s Falcon platform as a key milestone, describing it as a shift toward “agentic labor”—using AI agents to automate specialized industry tasks. Strong service execution and continued innovation in measurement tools like Crossix also cont

If you are looking at Veeva Systems and wondering whether the recent price is fair, expensive, or offers value, the next sections break down what the current valuation actually reflects. The stock last closed at US$167.68, after a mixed run with the price down 8.3% over the past week, roughly flat over 30 days with a 0.8% gain, and declining 23.6% year to date and 41.0% over the past year. Recent headlines around Veeva Systems have focused on its position as a healthcare software provider...

VEEV's Falcon and Vault AI deepen workflow automation across life sciences, while management expects AI revenues to remain immaterial in fiscal 2027.

The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Veeva (VEEV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

According to the average brokerage recommendation (ABR), one should invest in Veeva (VEEV). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Is VEEV a good stock to buy? We came across a bullish thesis on Veeva Systems Inc. on X.com by @tomicki. In this article, we will summarize the bulls’ thesis on VEEV. Veeva Systems Inc.’s share was trading at $188.66 as of June 1st. VEEV’s trailing and forward P/E were 34.68 and 21.28 respectively according to Yahoo […]

A number of stocks fell in the afternoon session after a stronger-than-expected jobs report signaled that the Federal Reserve may keep interest rates higher for longer.

Veeva Systems (NYSE:VEEV) introduced its new Falcon agentic AI platform, detailing capabilities aimed at clinical, regulatory, safety, and quality workflows. The company outlined early adopter timelines and broadened the rollout of Vault AI agents across its Vault applications. Veeva announced new platform commitments from Merck KGaA, Teva Pharmaceuticals, and Kindeva Drug Delivery, signaling wider enterprise use of its AI tools. Veeva Systems enters this phase of AI product rollout with...

Recent performance snapshot for Veeva Systems (VEEV) Veeva Systems (VEEV) has seen mixed share performance recently, with the stock roughly flat over the past day, higher over the past week and month, but lower over the past 3 months and year. See our latest analysis for Veeva Systems. At a share price of US$178.60, Veeva Systems has recently seen short term momentum pick up, with a 7 day share price return of 8.65%, even as the 1 year total shareholder return is down 38.40% and longer term...

VEEV lifts its full-year targets and highlights Falcon AI agents after a Q1 beat, with CRM migration wins and the Ostro deal shaping growth.

Life sciences cloud software provider Veeva Systems (NYSE:VEEV) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 16.3% year on year to $882.9 million. Guidance for next quarter’s revenue was better than expected at $903.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $2.24 per share was 4.9% above analysts’ consensus estimates.

Veeva Systems beats Q1 earnings and revenue estimates, raises fiscal 2027 guidance, and expands AI offerings as adoption of its software platforms expands.

Gunnar Hansen: Good afternoon, and welcome to Veeva's Fiscal 2027 First Quarter Earnings Conference Call for the quarter ended April 30, 2026. As a reminder, we posted prepared remarks on Veeva's Investor Relations website just after 1:00 p.m. Pacific today. Today's call will be used primarily for Q&A. With me today for Q&A are Peter Gassner, our Chief Executive Officer; Paul Shawah, EVP, Strategy; and Brian Van Wagener, our Chief Financial Officer.

The biggest insight hiding inside the recent Q1 FY27 earnings report from Veeva Systems (VEEV) is the stark divergence between management's artificial intelligence narrative and the structural realities of its legacy software business. While leadership dedicated significant time to detailing the launch of Veeva Falcon for agentic labor and the Ostro acquisition, the underlying financial tension centers entirely on the forced migration of its CRM customer base.

Moby summary of Veeva Systems Inc.'s Q1 2027 earnings call

Veeva Systems Inc Class A (NYSE:VEEV) reported stronger-than-expected first-quarter results and lifted its outlook for the remainder of the fiscal year, highlighting continued growth across its software and services businesses as well as increasing traction in artificial intelligence initiatives. The life sciences software provider posted adjusted earnings per share of $2.

Veeva Systems Inc (VEEV) reports strong revenue growth and introduces Veeva Falcon, an AI-driven product set to revolutionize drug development processes.

Veeva Systems (NYSE:VEEV) reported a strong start to the year, with Chief Executive Officer and Co-Founder Peter Gassner saying the company delivered results ahead of guidance as it expands its focus on artificial intelligence for the life sciences industry. On the earnings call, Gassner said total

The headline numbers for Veeva (VEEV) give insight into how the company performed in the quarter ended April 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Veeva (VEEV) delivered earnings and revenue surprises of +5.10% and +2.99%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?

Investing.com -- Veeva Systems Inc Class A (NYSE:VEEV) reported first-quarter results that exceeded analyst expectations, with adjusted earnings per share of $2.24 beating the consensus estimate of $2.14 by $0.10. Revenue reached $882.9 million, surpassing the $857.75 million estimate and marking a 16% increase from $759.0 million in the same quarter last year.

Life sciences cloud software provider Veeva Systems (NYSE:VEEV) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 16.3% year on year to $882.9 million. Guidance for next quarter’s revenue was better than expected at $903.5 million at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $2.24 per share was 4.9% above analysts’ consensus estimates.

US benchmark equity indexes were lower intraday, while oil prices rose amid renewed hostilities in t

The main US stock measures were mostly trending lower in Wednesday's premarket activity as traders a

June S&P 500 E-Mini futures (ESM26) are trending down -0.05% this morning as oil prices and bond yields climbed after the U.S. and Iran exchanged heavy fire in the Persian Gulf.

Life sciences cloud software provider Veeva Systems (NYSE:VEEV) will be announcing earnings results this Wednesday after market hours. Here’s what investors should know.

Shares of life sciences cloud software provider Veeva Systems (NYSE:VEEV) jumped 7.4% in the afternoon session after the company unveiled Falcon, a new artificial intelligence platform for drug development, and announced several major global customer commitments.